BRAF and melanoma: The first BRAF inhibitor in melanomas was vemurafenib, which demonstrated efficacy in BRAFV600E/K mutant melanomas in the BRIM-3 phase 3 randomized clinical trial that demonstrated the overall survival (OS) advantage compared to dacarbazine, with an objective response rate (ORR) of 48% [13].